New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Moderna Vaccine Data- https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data.

We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations.

The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31..

PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

Aggregate Data Collection Process
Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps:

• A CDC data team reviews and validates the information obtained from jurisdictions’ state and local websites via an overnight data review process.


• If more than one official county data source exists, CDC uses a comprehensive data selection process comparing each official county data source, and takes the highest case and death counts respectively, unless otherwise specified by the state.


• CDC compiles these data and posts the finalized information on COVID Data Tracker.


• County level data is aggregated to obtain state and territory specific totals.

This process is collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provide the most up-to-date numbers on cases and deaths by report date. CDC may retrospectively update counts to correct data quality issues.

Methodology Changes
Several differences exist between the current, weekly-updated dataset and the archived version:

• Source: The current Weekly-Updated Version is based on county-level aggregate count data, while the Archived Version is based on State-level aggregate count data.


• Confirmed/Probable Cases/Death breakdown:  While the probable cases and deaths are included in the total case and total death counts in both versions (if applicable), they were reported separately from the confirmed cases and deaths by jurisdiction in the Archived Version.  In the current Weekly-Updated Version, the counts by jurisdiction are not reported by confirmed or probable status (See Confirmed and Probable Counts section for more detail).


• Time Series Frequency: The current Weekly-Updated Version contains weekly time series data (i.e., one record per week per jurisdiction), while the Archived Version contains daily time series data (i.e., one record per day per jurisdiction).


• Update Frequency: The current Weekly-Updated Version is updated weekly, while the Archived Version was updated twice daily up to October 20, 2022.

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

Confirmed and Probable Counts
In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:

Deaths
CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (to

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates using the most recently available federal survey data.

Overall US COVID-19 Vaccine administration and vaccine equity data at county level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. 

The 2021-2022 School Learning Modalities dataset provides weekly estimates of school learning modality (including in-person, remote, or hybrid learning) for U.S. K-12 public and independent charter school districts for the 2021-2022 school year and the Fall 2022 semester, from August 2021 – December 2022.

These data were modeled using multiple sources of input data (see below) to infer the most likely learning modality of a school district for a given week. These data should be considered district-level estimates and may not always reflect true learning modality, particularly for districts in which data are unavailable. If a district reports multiple modality types within the same week, the modality offered for the majority of those days is reflected in the weekly estimate. All school district metadata are sourced from the National Center for Educational Statistics (NCES) for 2020-2021.

School learning modality types are defined as follows:

• In-Person: All schools within the district offer face-to-face instruction 5 days per week to all students at all available grade levels.


• Remote: Schools within the district do not offer face-to-face instruction; all learning is conducted online/remotely to all students at all available grade levels.


• Hybrid: Schools within the district offer a combination of in-person and remote learning; face-to-face instruction is offered less than 5 days per week, or only to a subset of students.

Data Information

• School learning modality data provided here are model estimates using combined input data and are not guaranteed to be 100% accurate. This learning modality dataset was generated by combining data from four different sources: Burbio [1], MCH Strategic Data [2], the AEI/Return to Learn Tracker [3], and state dashboards [4-20]. These data were combined using a Hidden Markov model which infers the sequence of learning modalities (In-Person, Hybrid, or Remote) for each district that is most likely to produce the modalities reported by these sources. This model was trained using data from the 2020-2021 school year. Metadata describing the location, number of schools and number of students in each district comes from NCES [21].


• You can read more about the model in the CDC MMWR: COVID-19–Related School Closures and Learning Modality Changes — United States, August 1–September 17, 2021.


• The metrics listed for each school learning modality reflect totals by district and the number of enrolled students per district for which data are available. School districts represented here exclude private schools and include the following NCES subtypes:
  
  
  
  • Public school district that is NOT a component of a supervisory union
  
  
  • Public school district that is a component of a supervisory union
  
  
  • Independent charter district
  
  
  
  


• “BI” in the state column refers to school districts funded by the Bureau of Indian Education.

Technical Notes

• Data from August 1, 2021 to June 24, 2022 correspond to the 2021-2022 school year. During this time frame, data from the AEI/Return to Learn Tracker and most state dashboards were not available. Inferred modalities with a probability below 0.6 were deemed inconclusive and were omitted. During the Fall 2022 semester, modalities for districts with a school closure reported by Burbio were updated to either “Remote”, if the closure spanned the entire week, or “Hybrid”, if the closure spanned 1-4 days of the week.


• Data from August

Note:
Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

The following apply to all three datasets:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and aut

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data.

We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated.

The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.

County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw